The somatic genetic changes identified in these 14 patients are well in line with known driver mutations in pancreatic cancer (Kamisawa et al., 2016) (Table 3): 13 had KRAS mutations (9 × G12D), four patients had additional TP53 mutations, 10 had additional EGFR (including one with wild‐type TP53) and three had additional SMAD4 (mothers against decapentaplegic homolog 4) mutations. The gene discussed is TP53; the disease is pancreatic neoplasm.